Voriconazole

Research use only, not for human use.

A a triazole antifungal agent that acts as a 14α-demethylase inhibitor.

A a triazole antifungal agent that acts as a 14α-demethylase inhibitor; used to treat and prevent invasive fungal infections including aspergillosis andcandidiasis and fungal infections caused by Scedosporium and Fusarium species. Fungal infection Approved(In Vitro):Voriconazole has great activity against S. apiospermum and C. neoformans with the MICs of 0.5 μg/mL and 0.125–0.25 μg/mL, respectively.Voriconazole inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth.(In Vivo):Voriconazole (5-20 mg/kg; p.o. for 21 days) prolongs survival in a dose-dependent fashion. Voriconazole (40 mg/kg/day) decreases the fungal burden in the lungs.

——

Animal Model:Male specific-pathogen-free BALB/cByJ mice Dosage:1, 5, 20 mg/kg/day Administration:P.o. once daily for 21 days Result:Improved survival in a dose-response fashion, with median survival times (MSTs) of 21, 28, and 35 days with doses of 1, 5, and 20 mg/kg, respectively.

UK-109496 | UK109496 | UK 109496

Microbiology/Virology

Fungal

14-αDemethylase

Infection

Fungal Infection

137234-62-9

349.3105

C16H14F3N5O

>98% (HPLC)

10 mM in DMSO

C[C@@H](C1=NC=NC=C1F)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βS)-

(-20℃)

With Ice Pack

≥ 2 years